Advertisement

Topics

STAT Plus: These companies actually want to pay higher fees — and the FDA is poised to make that happen

04:30 EDT 23 Aug 2017 | STAT

Makers of over-the-counter drugs may soon have to pay for federal review of their products, just like pharmaceutical makers.

Original Article: STAT Plus: These companies actually want to pay higher fees — and the FDA is poised to make that happen

NEXT ARTICLE

More From BioPortfolio on "STAT Plus: These companies actually want to pay higher fees — and the FDA is poised to make that happen"

Advertisement
Quick Search
Advertisement
Advertisement